You are here: Industry Insights > RNAi

News List

Arrowhead Pharma purchases land ahead of new manufacturing facility buildout CPhIonline
December 22, 2021
New campus will support the company as it approaches potential commercialisation of its rapidly progressing clinical candidates.
Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications prnewswire
July 22, 2021
Mirimus, Inc., today announced a strategic collaboration with Biogen Inc. (NASDAQ: BIIB) focused on the development of RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications.
Dicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement americanpharmaceuticalreview
May 25, 2021
Dicerna announced that Boehringer Ingelheim has accepted a GalXC™ RNAi candidate for advancement under the existing agreement between the companies for the discovery and development of novel therapies for the treatment of chronic liver diseases.
PerkinElmer to Acquire Horizon Discovery americanpharmaceuticalreview
November 04, 2020
PerkinElmer and Horizon Discovery Group have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire Horizon for approximately $383 million.
Alnylam Partners with Sharp contractpharma
September 21, 2020
Signs an agreement for the packaging of Alnylam’s approved RNAi therapeutic in European markets.
Arrowhead Pharmaceuticals files for regulatory clearance to begin phase 1/2a study of ARO-ENaC for treatment of cystic fibrosis pharmaceutical-business-review
April 15, 2020
Arrowhead Pharmaceuticals has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-ENaC.
Alnylam’s gene-silencing efforts get $2 billion Blackstone backing expresspharma
April 15, 2020
Alnylam is the first drugmaker to win US approval for a treatment using the Nobel prize-winning RNA interference (RNAi) technology and is currently developing other RNAi drugs to treat a range of conditions, including rare bleeding disorders.
Vir Biotechnology and Alnylam partner in fight against Covid-19 pharmaceutical-technology
March 09, 2020
Clinical-stage immunology firm Vir Biotechnology and biopharmaceutical company Alnylam Pharmaceuticals have extended their existing partnership to advance RNAi therapeutics to treat coronavirus infections, including Covid-19.
Givlaari approved in EU following recent CHMP nudge pharmatimes
March 06, 2020
Alnylam has received approval from the European Commission for its second RNAi medicine - this time an acute hepatic porphyria (AHP) drug, Givlaari (givosiran).
Mallinckrodt, Silence Therapeutics Enter RNAi Alliance contractpharma
July 24, 2019
Aims to develop and commercialize RNAi therapeutics for complement-mediated diseases.

Previous page 1 2 Next page